title: Bisphosphonates, cancer, and osteonecrosis--a single practice experience.
abstract: Intravenous bisphosphonates have come into increasing use to protect cancer patients from adverse boney events. The prevalence of use, demographics of a treatment population, and occurrence of a particular side effect are explored in this article.
authors.affiliation: Medical Oncology Hematology Consultants, Newark, DE, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Guarino
authors.forename: Constance E
authors.initials: CE
authors.lastname: Hill
authors.forename: Ketan
authors.initials: K
authors.lastname: Patel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D003646:Debridement; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D008297:Male; D008336:Mandibular Diseases / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D008439:Maxillary Diseases / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D000077268:Pamidronate; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate